Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target
NEW YORK, December 30, 2025, 12:44 ET — Regular session Johnson & Johnson shares edged lower on Tuesday after the company said it completed its $3.05 billion cash purchase of cancer-therapy developer Halda Therapeutics. The stock was down about 0.2% at $207.12 in midday trading. Executive vice president Jennifer Taubert called the closing a “strategic milestone” as J&J flagged about $0.20 of dilution to adjusted earnings per share — profit per share excluding certain one-time items — split between 2025 and 2026. Johnson & Johnson Investor Relations The closing gives J&J a new platform aimed at developing oral, targeted cancer